Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

liefitegrast

- PMLiVE

Mylan facing US anticompetitive practice probe

Senate judiciary committee calls for fair competition review over EpiPen sales

- PMLiVE

Takeda launches drug discovery biotech

Hopes Bridge Medicines will streamline the development process

- PMLiVE

The Global Awards 2016 finalists announced

GSW Worldwide’s virtual reality epilepsy campaign among the 145 shortlisted entries

Sanofi reception

Manufacturing issues scupper Sanofi’s sarilumab launch plans

FDA turns down the rheumatoid arthritis drug’s marketing application after routine inspection

AstraZeneca AZ

AstraZeneca shaken by FDA partial hold on durvalumab trial

Aims to resume trial recruitment as soon as possible after bleeding side effects curb study

National Institute for Health and Care Excellence NICE logo

NICE backs Amicus Therapeutics’ Galafold

Recommends oral alternative for treating Fabry disease

- PMLiVE

Merck gets early OK for Keytruda in first-line lung cancer

FDA fast-tracks approval of PD-1/PD-L1 inhibitor for treatment of NSCLC

- PMLiVE

GSK’s blockbuster hopeful Shingrix filed in US

Clinical data showed shingles vaccine had 90% efficacy in elderly patients

- PMLiVE

After delay, Merck gets US approval for serious infection drug

Zinplava anticipated to accrue $300m in sales by 2020

Bristol-Myers Squibb (BMS) building

Keytruda, Opdivo narrow Tecentriq’s lead in bladder cancer

BMS’ drug is currently under FDA and EMA review in advanced urothelial carcinoma

Eli Lilly HQ

Lilly snags first approval for sarcoma drug Lartruvo

Granted accelerated approval by the FDA becoming first front-line STS therapy for 40 years

Roche Basel Switzerland

Lung cancer OK for Tecentriq sets up showdown with Merck and BMS

Broad label will aid Roche’s PD-L1 inhibitor in head-to-head NSCLC market-share battle

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links